Ailar Jamalli

Ailar Jamalli

Auto-generated profile, based on publicly available information

Ailar Jamalli

Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2009 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
KSKaren Shahbabian
Karen Shahbabian
AJAilar Jamalli
Ailar Jamalli
LZLéna Zig
Léna Zig
HPHarald Putzer
Harald Putzer
In contrast to Escherichia coli, initiation of mRNA decay in Gram‐positive organisms is poorly understood. We studied the fate of the highly structured RNAs generated by premature transcription termination of S‐adenosylmethionine (SAM)‐dependent riboswitches in Bacillus subtilis. An essential protein of earlier unknown function, YmdA, was identified as a novel endoribonuclease (now called RNase Y) that was capable of preferential cleaving in vitro of the 5′ monophosphorylated yitJ riboswitch upstream of the SAM‐binding aptamer domain. Antiterminated full‐length yitJ mRNA was not a substrate for RNase Y in vivo and in vitro, transcripts capable of forming the antiterminator were only cleaved in the presence of SAM. Turnover of 10 other SAM‐dependent riboswitches was also initiated by RNase Y. Depletion of this ribonuclease increased the half‐life of bulk mRNA more than two‐fold. This indicates that RNase Y might be not only important for riboswitch RNA turnover but also as a key player in the initiation of mRNA decay in B. subtilis. About 40% of the sequenced eubacterial species have an RNase Y orthologue.

20 January 2008 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
ISInés Li de la Sierra-Gallay
Inés Li de la Sierra-Gallay
LZLéna Zig
Léna Zig
AJAilar Jamalli
Ailar Jamalli
HPHarald Putzer
Harald Putzer

10 January 2020 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
EKEsmat Kamali
Esmat Kamali
AJAilar Jamali
Ailar Jamali
AAAbdollah Ardebili
Abdollah Ardebili
FEFreshteh Ezadi
Freshteh Ezadi
Alireza MohebbiAlireza Mohebbi
Alireza Mohebbi
Objectives: Pseudomonas aeruginosa is known as a leading cause of nosocomial infections worldwide. Antimicrobial resistance and biofilm production, as two main virulence factors of P. aeruginosa, are responsible for the persistence of prolonged infections. In this study, antimicrobial susceptibility pattern and phenotypic and genotypic characteristics of biofilm of P. aeruginosa were investigated. Results: A total of 80 clinical P. aeruginosa isolates were obtained. Isolates showed resistance to all antibiotics with a rate from 12.5% (n = 10) against amikacin and piperacillin/tazobactam to 23.75% (n = 19) to levofloxacin. Multidrug-resistant P. aeruginosa accounted for 20% (n = 16). 83.75% (n = 67) of isolates showed biofilm phenotype. All three biofilm-related genes were found simultaneously in 87.5% (n = 70) of P. aeruginosa and 13.5% (n = 10) of the isolates had none of the genes tested. From the results of the present study, combination therapy including an anti-pseudomonal beta-lactam (piperacillin/tazobactam or ceftazidime) and an aminoglycoside or carbapenems (imipenem, meropenem) with fluoroquinolones in conjunction with an aminoglycoside can be used against Pseudomonas infections. However, reasonable antimicrobial use and high standards of infection prevention and control are essential to prevent further development of antimicrobial resistance. Combination strategies based on the proper anti-pseudomonal antibiotics along with anti-biofilm agents can also be selected to eradicate biofilm-associated infections.

16 December 2021 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
EKEsmat Kamali
Esmat Kamali
AJAilar Jamali
Ailar Jamali
AIAhdieh Izanloo
Ahdieh Izanloo
AAAbdollah Ardebili
Abdollah Ardebili
Background: Biofilms are a main pathogenicity feature of Pseudomonas aeruginosa and has a significant role in antibiotic resistance and persistent infections in humans. We investigated the in vitro activities of antibiotic ceftazidime and enzyme cellulase, either alone or in combination against biofilms of P. aeruginosa. Results: Both ceftazidime and cellulase significantly decreased biofilm formation in all strains in a dose-dependent manner. Combination of enzyme at concentrations of 1.25, 2.5, 5, and 10 U/mL tested with 1/16× MIC of antibiotic led to a significant reduction in biofilm biomass. Cellulase showed a significant detachment effect on biofilms at three concentrations of 10 U/mL, 5 U/mL, and 2.5 U/mL. The MIC, MBC, and MBEC values of ceftazidime were 2 to 4 µg/mL, 4 to 8 µg/mL, and 2048 to 8192 µg/mL. When combined with cellulase, the MBECs of antibiotic showed a significant decrease from 32- to 128-fold. Conclusions: Combination of the ceftazidime and the cellulase had significant anti-biofilm effects, including inhibition of biofilm formation and biofilm eradication in P. aeruginosa. These data suggest that glycoside hydrolase therapy as a novel strategy has the potential to enhance the efficacy of antibiotics and helps to resolve biofilm-associated wound infections caused by this pathogen.

1 June 2020 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
FEFereshteh Ezadi
Fereshteh Ezadi
AJAilar Jamali
Ailar Jamali
AHAhmad Heidari
Ahmad Heidari
NJNaemeh Javid
Naemeh Javid
AAAbdollah Ardebili
Abdollah Ardebili
Colistin resistance rates are arising worldwide among the multidrug-resistant Gram-negative bacilli, including Acinetobacter baumannii. A new type of resistance, heteroresistance, has also been reported to colistin in clinical A. baumannii isolates. This study investigated the presence of colistin heteroresistance in carbapenem-resistant A. baumannii clinical isolates. Different clinical specimens from the hospitalized patients were investigated for A. baumannii. MICs to imipenem, meropenem, and colistin were determined by broth microdilution. PCR was performed for detection of OXA-type carbapenemase genes (blaOXA-23-like, blaOXA-24/40-like, blaOXA-51-like, blaOXA-58-like, and blaOXA-143-like). Heteroresistance to colistin was examined using population analysis profiles (PAPs) method. Genotypic relatedness of the isolates was analyzed by enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR). Overall, 71 isolates of A. baumannii were recovered from clinical specimens. Of these, 38.03% (n = 27) and 61.97% (n = 44) were carbapenem-susceptible and carbapenem-resistant, respectively. In addition, 94.36% (67/71) of isolates were susceptible to colistin with MIC between 0.25 and 2 µg/mL. Among the 44 selected carbapenem-resistant, colistin-susceptible isolates, the frequency of blaOXA-51-like, blaOXA-23-like, and blaOXA-24/40-like genes was 100%, 77.27%, and 43.18%, respectively. The 20.45% of isolates (n = 9/44) were characterized as colistin-heteroresistant with subpopulations growing at 6-8 μg/mL, whereas 4.54% (n = 2/44) presented heterogeneous subpopulations growing at up to 1 μg/mL of colistin. ERIC‑PCR typing clustered A. baumannii isolates to 10 common types (CT1-CT10) containing isolates from different hospitals and 12 single types (ST1-ST12). Importantly, A. baumannii with colistin heteroresistance phenotype was common. This could be a great concern, since that colistin is often used as a last-resort drug for treatment of A. baumannii infections, highlighting the care is necessary with colistin monotherapy. In addition, more effective strategy and surveillance are required to confine and prevent the inter- and/or intra-hospital dissemination of A. baumannii between our therapeutic centers.